At o2h, we understand that precise, reliable, and reproducible data is the cornerstone of successful drug discovery. Our comprehensive assay services, including Primary, Orthogonal, and Selectivity assays, are designed to accelerate your drug development pipeline with unmatched scientific rigor.
Primary screening is the initial step in drug discovery, where a large library of compounds is tested to identify potential drug candidates. This phase focuses on compounds that directly engage with biological targets, such as proteins, enzymes, and receptors.
We offer a wide range of target-based approaches to evaluate small molecules and other therapeutic modalities. Our evaluations include biochemical activity, biophysical binding, and transcriptional activity. Additionally, we support phenotype-based approaches utilising high-content screening (HCS), morphology-based changes, and downstream functional outcomes. These assays can be customised to match your specific target and therapeutic area.
Subsequently, our orthogonal validation involves using different methods to confirm the activity and effectiveness of drug candidates identified in primary screening. This approach features diverse methodologies to verify results and enhance data reliability, mitigating risks and identifying potential false positives early in the process. This validation can include biochemical/biophysical, cell-based, and complementary phenotypic assays, increasing confidence in selected leads before moving forward and ensuring that our findings are not artifacts of a single assay system.
We further optimise your drug candidates by assessing how selectively they interact with their intended targets compared to similar biological targets. This assessment involves testing against closely related family members to determine specificity and evaluating activity across different species to understand potential side effects and off-target interactions.
Emphasizing the interconnectedness of these processes is crucial for ensuring that only the most promising candidates advance to clinical trials, ultimately leading to safer and more effective therapeutics. This holistic approach empowers you to make informed decisions in your drug development strategy.
To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.
